This pivotal Phase III clinical trial adopts a multicenter,randomized,standard-of-care-controlled,open-label study design across the country,aiming to further systematically validate the efficacy and safety of GC101 Injection in patients with Type 2 SMA.The study plans to enroll 50 subjects aged 2-12 years with Type 2 SMA nationwide,led by the Seventh Medical Center of the General Hospital of the People's Liberation Army in collaboration with multiple authoritative medical institutions.
The initiation meeting was chaired by Professor Feng Zhichun.Attendees included leading experts from the Seventh Medical Center of the General Hospital of the People's Liberation Army,such as Professor Feng Zhichun,Dr.Ma Xiuwei,Director of the Department of Neurology,and Dr.Xu Juan,Director of the Clinical Trial Institution Office,as well as representatives from the sponsor,Genecradle Therapeutics,including Dr.Dong Xiaoyan,Co-founder and General Manager,and Dr.Yu Shuangqing,Deputy General Manager.During the meeting,both parties engaged in in-depth discussions on core issues such as the trial protocol design,subject recruitment strategies,and key points of trial implementation.All participants expressed their commitment to strictly follow GCP guidelines,prioritizing the safety and rights of subjects,and to scientifically and standardly advance the clinical trial.
In his opening remarks,Professor Feng Zhichun expressed his honor in contributing to the national prevention and treatment of rare diseases.He noted that although there are currently drugs available for SMA patients,there are still many unmet clinical needs,and the development of GC101 Injection is expected to fill the relevant treatment gaps.Professor Feng emphasized that the Phase III clinical trial is a crucial step before a new drug can be marketed.The research team will maintain a rigorous scientific attitude,strictly implement the trial protocol,and ensure the authenticity and effectiveness of the data.He also thanked the GCP institution for its professional guidance and looked forward to collaborative efforts from all parties to expedite the drug's market launch and benefit patients.
Dr.Dong Xiaoyan highly praised the positive outcomes achieved by the research team in the Phase I/II clinical studies of GC101 Injection.She expressed the hope that this pivotal Phase III study will further confirm the drug's safety and efficacy.The active enrollment intentions shown by the current SMA patient community fully reflect the urgent anticipation for domestically developed innovative gene therapy drugs.Genecradle Therapeutics looks forward to deepening collaboration with the research team to achieve breakthrough progress in the SMA treatment field with GC101 Injection,making it a significant milestone in gene therapy and setting a new benchmark for rare disease drug development in China and globally.